Recent studies show that brain-derived neurotrophic factor (BDNF) decreases feeding and body weight after peripheral and ventricular administration. BDNF mRNA and protein, and its receptor, TrkB, are widely distributed in the hypothalamus and other brain regions. However, there are few reports on specific brain sites of actions for BDNF. We evaluated the effect of BDNF, given into the ventromedial nucleus of the hypothalamus (VMH), on normal, deprivation-and NPY-induced feeding behavior and body weight.
Introduction
The VMH is a brain area important to the regulation of energy metabolism. Early studies indicated that VMH lesions resulted in hyperphagia and obesity (28, 38, 66 ) whereas electrical stimulation of the VMH immediately suppressed feeding and induced lipolysis (65) . Glucose sensing neurons (7, 27, 55, 74, 75) and receptors for neuropeptides important to energy metabolism have been identified in the VMH, including leptin (20) (17, 22) , (13, 51), melanocortin (26), NPY (43), corticotrophin releasing hormone (CRH) (49), cholecystokinin (CCK) (12), insulin (33), and orexin (44) receptors. Many biological agents given into the VMH have been demonstrated to affect feeding. Food intake is inhibited by administration of histamine (4, 47) , glucagonlike peptide 1 (70) , serotonin agonists (25), urocortin (58), CCK (79), leptin (51) and insulin (78), while thyroid hormone (T3) (40), gamma-aminobutyric acid (GABA) or GABA agonists (32, 34, 35), norepinephrine (73) , orexin (74) , and NPY induce feeding after administration into the VMH (5, 9, 24, 31, 43, 56, 76) .
Anatomically, the VMH receives inputs from regions important to the regulation of energy metabolism, including the hypothalamic arcuate nucleus (ARC) (2, 14, 23) , lateral hypothalamus (LH) (18, 67, 80), amygdala (45, 50), and lateral septum. The VMH also projects to ARC (77), PVN (42, 52), LH (72, 80) , dorsomedial nucleus of the hypothalamus (46, 80), amygdala (6, 68) , lateral septum (68), ventral tegmental area (VTA) (68), nucleus accumbens (6) and nucleus of the solitary tract (6) . These behavioral and neuroanatomical data provide evidence for the importance of the VMH in regulation of energy metabolism.
Brain-derived neurotrophic factor (BDNF) has recently been reported to affect energy metabolism. ICV BDNF decreased feeding and body weight gain in animals (62) . BDNF +/-heterozygous animals displayed hyperphagia and obesity(36), and exogenous BDNF reversed the phenotype. Human patients with BDNF receptor (TrkB) defects exhibit hyperphagia and obesity (91) . Low levels of plasma BDNF have been found in obese patients with type 2 diabetes and metabolic syndrome (21). This evidence indicates that BDNF is important in the regulation of energy metabolism, but information on sites of BDNF action in the central nervous system is limited. Low BDNF expression was observed in the hypothalamus of BDNF +/-heterozygous animals, including the PVN and VMH (36). Bariohay et al (3) reported significant decreases in feeding and body weight gain during chronic infusion of BDNF in the dorsal ventral complex (DVC), and our previous work indicates that the PVN is an important site of BDNF action (85, 86) . BDNF in the VMH may also play an important role in the regulation of energy metabolism. Both mRNA and protein for BDNF and its receptor TrkB have been identified in the VMH (8, 36, 87, 90). Low levels of BDNF in the VMH are accompanied by hyperphagia and obesity (36) and animals lacking the orphan nuclear steroidogenic factor-1 (SF-1) receptor develop BDNF deficiency and VMH abnormalities, and also display hyperphagia and obesity (11, 48, 82, 92) . Recent studies indicate that expression of BDNF in the VMH is regulated by leptin (39) and melanocortins (89) , two key mediators of energy metabolism. Based on these data, we set out to determine whether the VMH is an important site of BDNF action.
We first tested the effect of a single injection of BDNF in the VMH on normal feeding and deprivation-induced feeding. We then determined whether these effects could be reversed by preadministration of the TrkB-Fc fusion protein, which functionally blocks binding between BDNF and the TrkB receptor. We also performed a conditional taste aversion study to determine whether BDNF into this brain area results in feelings of malaise, which could potentially explain reductions in feeding. Finally, we tested the interaction between BDNF and NPY by measuring the effect of BDNF on NPY-induced feeding. Our study demonstrated that 1) a single injection of BDNF in the VMH significantly reduces feeding and body weight gain in normal and food-deprived animals for up to 48 h; 2) pretreatment with TrkB-Fc significantly blocks BDNF-induced anorexia; 3) BDNF, at doses that effectively inhibit feeding (0.1-1 µg), does not result in a conditioned taste aversion; 4) BDNF significantly blocks NPY-induced feeding.
Methods
Animals: Male Sprague-Dawley rats (Harlan, Madison, WI) weighing 280-320 g were housed individually in cages with a 12 h light/12 h dark photo-cycle (lights on at 07:00) in a room at 21-22 °C. Teklad lab Chow and water were allowed ad libitum, except where noted. All experimental study protocols were approved by the VAMC Institutional Animal Care and Use Committee prior to commencement.
Cannulation and Verification of Placement: Rats were anesthetized with intramuscular Xylazine (3.5 mg/kg) and Ketamine (20 mg/kg) and were fitted with 28-gauge stainless steel guide cannulae placed just above the VMH either unilaterally or bilaterally.
Stereotaxic coordinates were determined from the rat brain atlas of Paxinos and Watson (61) and are as follows: 0.6 mm lateral and 2.5 mm posterior to bregma, and 8.5 mm below the skull surface. The injector extended 1 mm further than the end of the guide cannula. The animals were given at least one week to recover following surgery before experimental trials. After terminal experiments the rats were decapitated and whole brain tissues were taken out and soaked in 10% formalin solution for at least 48 h. The brain tissues were sectioned by cryostat at a thickness of 50 µm, mounted on gelatin-coated slides, stained with 0.1% thionin, and treated with ethanol (from 30% to 100%) and
Clearing Agent (Electron Microscopy Sciences, Hatfield, PA). After the slides were dried, injection placement was determined microscopically at 10x, using the brain atlas of Paxinos and Watson (61) as a reference. Placements of the unilateral injection sites for the studies of BDNF effects on normal and deprivation-induced feeding, and bilateral injection sites for the studies of BDNF effects on normal feeding are summarized in Fig.   1 , and a photomicrograph of representative histology with bilateral cannulation is shown in Fig. 2 . A cannula was deemed correct if the histological examination indicated that the injection was within a 0.25 mm diameter from the targeted site. This rationale is based on diffusion coefficients for the injection volume delivered (57) and our previous work showing effectiveness within this range (85, 86) . Data from animals with misplaced cannulae were excluded from the data analysis. Histological examination of brain tissue to verify injection site was not possible in some studies as rats were undergoing additional studies. In this situation we used feeding response to injected NPY as a behavioral assay to determine correct cannulae placement as verified in previous studies (5, 9, 24, 31, 43, 56, 76) . According to this assay, cannula placement is deemed correct if the animal consumes more than 2 g chow within 2 h after 100 pmol NPY. Animals not responding to NPY are excluded from the study. Injections: Volume of 0.5 µl was injected slowly over 2 min for TrkB-Fc and over 30 sec for vehicle and other compounds, with injector left in place an additional 15 sec to ensure extrusion from the tip, and to minimize distribution of drug upwards on the cannula tract.
In total, animals received less than 10 injections. Injection sites were examined by light microscopy for tissue damage in the present studies and none was found.
Experiments: 1) Effect of BDNF on normal feeding
Food was allowed ad libitum before and during the experimental period. Eighteen rats were injected unilaterally with aCSF, 0.1 µg, 0.3 µg, or 0.5 µg BDNF just before the dark phase (7:00 pm). Food intake was measured at 1, 2, 4, 24 and 48 h following injection.
Body weight was measured at 0 h and at 24 and 48 h after injection. Each animal received each treatment once with at least 72 h between treatment to allow for clearance of BDNF from the CNS and for normal feeding patterns to be re-established. Treatments were given in a randomly selected Latin square design to avoid a treatment-order confound. Sixteen rats had correct cannula placement (verified by histology), and therefore were included in the final statistical analyses. Another set of 17 rats with bilateral cannulae were injected with 0.1, 0.3, 0.5, 1.0 and 3.0 µg BDNF on each side at 2:00 pm. Food intake and body weight change were measured at 24 and 48 h following injection. After excluding 3 rats with incorrect cannula placement (verified by histology), 14 rats were included in the final statistical analyses.
2) Effect of BDNF on deprivation-induced feeding
Eighteen rats were injected unilaterally with aCSF or BDNF (0.1 µg, 0.3 µg, or 0.5 µg) after 18 h food deprivation, and were given food immediately after injection. Food intake was measured at 1, 2, 4, 24 and 48 h following injection. Body weight was measured at 0 h and at 24 and 48 h after injection. Each animal received each treatment once with at least 72-96 h between treatments. Sixteen rats had correct cannula placement (verified by histology), and were included in the statistical analyses. Another set of 20 rats was bilaterally injected with 0.1, 0.3, 0.5 or 1.0 µg BDNF on each side. Each animal received each treatment once with at least 72-96 h between treatments. Correct placement was determined by response to NPY. All rats were deemed to have correct placement and were included in the statistical analyses.
3) Effect of TrkB-Fc fusion protein on BDNF-suppressed feeding
TrkB-Fc is a fusion protein that consists of an extracellular domain of the TrkB receptor and a Fc domain of IgG. TrkB-Fc binds to BDNF with high affinity and thus functionally blocks BDNF binding to its receptor. Twenty-four rats were injected bilaterally with one of the following combined treatments on each side: 1) aCSF + aCSF, 2) aCSF + 0.5 µg BDNF, 3) 0.5 µg TrkB-Fc + 0.5 µg BDNF, 4) 0.5 µg TrkB-Fc + aCSF.
The second injection was given 10-15 min after the first injection. Food intake and body weight was measured at 0, 24 and 48 h following the second injection. Each animal received each treatment once with at least 72 h between treatments. The dose of TrkB-Fc was chosen based on effective dose ranges from published in-vivo studies (30, 41, 64, 69) and pilot studies in our laboratory. After excluding 3 rats that did not respond to NPY, 21 rats were included in the statistical analysis.
4) The effect of VMH-injected BDNF on preference for saccharin solution
In a separate group of animals, the two-bottle preference test was used to determine whether BDNF results in aversive consequences after administration into the VMH. The procedures for the experiment have been previously described (84) . In brief, drinking water was allowed only between 10:30 -11:00 am for thirty bilaterally VMH-cannulated rats each day for 7 d. During water access, two bottles of water were presented. The rats were then randomly divided into 5 groups (with an even distribution of body weight) and
given 15 ml of 0.1% saccharin immediately followed by injection on each side with either aCSF or BDNF (0.1, 0.3, 0.5, or 1.0 µg). This conditioned stimulation was repeated once after 2 d, and the animals were then given the choice of water and saccharin in the absence of drug administration 2 d later. To avoid the possible confound of bottle placement, initial position and order of presentation of the saccharin bottle were counterbalanced across subjects, and the two-bottle test was repeated two days later in which the 2 bottle positions were reversed. Intake of water and saccharin during 24 h was measured, and the mean of the 2 tests was calculated. After excluding 1 rat that did not respond to VMH NPY, 29 rats were included in the statistical analyses.
5) Effect of BDNF on NPY-induced feeding:
Food was allowed ad libitum before and during the experimental period. Ten VMH bilaterally cannulated rats were randomly assigned to one of 6 treatments: 1) aCSF + aCSF, 2) aCSF + NPY (100 pmol), 3) BDNF (0.1 µg) + NPY (100 pmol), 4) BDNF (0.3 µg) + NPY (100 pmol), 5) BDNF (0.5 µg) + NPY (100 pmol), or 6) BDNF (0.5 µg) + aCSF. The first injection was made bilaterally at 7:00 am, and the second injection was made unilaterally 4 h later (11:00 am) on the alternate side on each experimental day. The 4 h delay was used in an effort to match the delayed effect of BDNF on feeding behavior in food-deprived animals. Each animal received each treatment once with at least 72 h between treatment to allow for clearance of BDNF from the CNS and for normal feeding patterns to be re-established. Food intake was measured at 1, 2, and 4 h following the second injection. All 10 rats responded to NPY and were included in the statistical analyses. When main effects were observed, post-hoc analysis was performed using multiplecomparison contrasts. For the conditioned taste aversion experiment, data were analyzed by a one-factor ANOVA followed by Fisher's least-significant difference t-test to compare means.
RESULTS

1) Effect of BDNF on normal feeding
Unilateral injections of BDNF did not significantly affect feeding within the first 4 h post-injection (Fig. 3A) , but 0.5 µg BDNF significantly decreased feeding in the 4-24 h post-injection interval by 21.6% (P = 0.0056, Fig. 3B ); by 17.4% (P = 0.0084) in the 0-24 h interval, and by 13.2% (P = 0.0061; Fig. 3B ), respectively, in the 0-48 h interval. Bilaterally injected BDNF dose-dependently inhibited normal feeding (Fig. 4A) . At 24 h after injection, BDNF at the 1 and 3 µg doses significantly inhibited normal feeding by 10.3% (P = 0.024) and 16.3% (P = 0.0005), respectively. In the 24-48 h interval, BDNF at 0.5, 1, and 3 µg significantly inhibited normal feeding by 9.5% (P = 0.0073), 7.5% (P = 0.0329) and 9.7% (P = 0.0066), respectively. In the 0-48 h post-injection interval, BDNF at 1 and 3 µg significantly inhibited normal feeding by 8.9% (P = 0.0112) and 12.9% (P = 0.0003), respectively. In the 0-24 h post-injection interval, BDNF at 0.5, 1, and 3 µg significantly inhibited body weight gain by 53.9% (P = 0.0471), 60.1% (P = 0.0295) and 98.8% (P = 0.0004), respectively (Fig. 4B ). In the 0-48 h interval, BDNF at 0.5, 1, and 3 µg inhibited body weight gain (P = 0.0412, P = 0.0074 and P = 0.0004, respectively, Fig. 4B ).
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2) Effect of BDNF on deprivation-induced feeding Unilateral injections of BDNF did not significantly affect feeding within the first 4 h post-injection. In the 4-24 h post-injection interval, BDNF at 0.3 and 0.5 µg significantly decreased feeding by 12.3% (BDNF, 18.37 ± 0.69 g vs. aCSF, 21.29 ± 0.81 g; P = 0.0163) and 15.8% (BDNF, 17.93 ± 0.85 g vs. aCSF, 21.29 ± 0.81 g; P = 0.0025), respectively. In the 0-24 h post-injection interval, BDNF at 0.1, 0.3 and 0.5 µg significantly reduced feeding by 7.8% (BDNF, 29.16 ± 0.96 g vs. aCSF, 31.61 ± 0.91 g; P = 0.0196), 8.1% (BDNF, 29.04 ± 0.81 g vs. aCSF, 31.61 ± 0.91 g; P = 0.0147) and 9.3% (BDNF, 28.66 ± 0.72 g vs. aCSF, 31.61 ± 0.91 g; P = 0.0056). In the 0-48 h postinjection interval BDNF reduced feeding and body weight gain in a dose dependent pattern, but these changes did not reach statistical significance (P > .05, data not shown).
Similar to the data from unilateral BDNF administration, bilateral-injected BDNF did not inhibit feeding at 4 h after injection (Fig. 5A ). In the 4-24 h post-injection interval, BDNF at 0.3, 0.5 and 0.1 µg dose dependently inhibited deprivation-induced feeding by 13.4% (P = 0.0077), 18.1% (P = 0.0004) and 22.1% (P < 0.0001), respectively ( Fig. 5B ). BDNF at 0.1, 0.3, 0.5 and 1 µg in the 0-24 h post-injection interval significantly reduced feeding by 7.0% (P = 0.0234), 11.8% (P = 0.0002), 17.5% (P < 0.0001) and 17.0% (P < 0.0001), respectively. BDNF-induced reductions in feeding in the 24-48 h post-injection interval did not reach statistical significance. During the 0-48 h post-injection interval, BDNF at 0.3, 0.5 and 1 µg significantly decreased feeding by 6.8% (P = 0.0111), 13.3% (P < 0.0001) and 14.3% (P < 0.0001), respectively (Fig. 5B ). In the 0-24 h post-injection interval, BDNF at 0.1, 0.3, 0.5 and 1 µg dramatically decreased body weight gain by 16 .4% (P = 0.0551), 27.1% (P = 0.0019), 42.9% (P < 0.0001) and 45.4%, (P < 0.0001), respectively (Fig. 5C ). In the 0-48 h post-injection interval, BDNF at 0.3, 0.5 and 1 µg significantly and dose-dependently decreased body weight gain by 34.5% (P = 0.0028), 43.6% (P = 0.0002) and 58.5%, (P < 0.0001), respectively (Fig. 5C ).
3) Effect of TrkB-Fc fusion protein on BDNF-induced feeding inhibition
In this experiment, the second injection (BDNF or aCSF) was made 10-15 min after the first injection (TrkB-Fc or aCSF). During the 0-24 h post-injection interval BDNF at 0.5 µg significantly decreased feeding by 19 .4% (P < 0.0001, Fig. 6A ) and body weight gain (P < 0.0001, Fig. 6B ). Pre-administration of 0.5 µg TrkB-Fc significantly attenuated BDNF-induced anorexia by 13.7% (P = 0.0011, Fig. 6A ) and body weight decrease (P = 0.0426, Fig. 6B ). During the 24-48h post-injection interval, BDNF significantly decreased feeding by 6.2% (P = 0.0077, Fig. 6A ) and body weight gain (P = 0.0028, Fig.   6B ); pre-administration of TrkB-Fc attenuated BDNF-induced anorexia by 4.7% and body weight loss, but this did not reach statistical significance (P = 0.2122, and P = 0.2147, respectively). During the 0-48 h post-injection interval, BDNF significantly decreased feeding by14.3% (P < 0.0001, Fig. 6A ) and body weight gain (P < 0.0001, Fig.   6B ), while pretreatment with TrkB-Fc significantly attenuated BDNF-induced feeding inhibition by 9% (P = 0.0073, Fig. 6A ) and BDNF-induced body weight loss (P < 0.0191, Fig. 6B ).
4) The effect of VMH-injected BDNF on preference for saccharin solution
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In the conditioned taste aversion experiment, the percentage of fluid intake attributed to saccharin was 91.4 ±1.8% for aCSF, 78.1 ± 8.2% for 0.1 µg BDNF, 86.8 ± 7.2% for 0.3 µg BDNF, 80.8 ± 6.1% for 0.5 µg BDNF, and 71.3 ± 8.9% for 1.0 µg BDNF, respectively. There was no main effect of BDNF on the intake of saccharin solution (P = 0.3013).
5) Effect of BDNF on NPY-induced feeding
Injection of NPY into the VMH significantly increased food intake at 1 h after injection (P= 0.0018, Fig 7) , and pre-administration of BDNF (0.5 µg) significantly decreased NPY-induced feeding by 67.4% (P = 0.0139, Fig. 7 ). In the 1-2 h and 2-4 h post-injection intervals, there was no main effect on feeding (Fig. 7) . However, in the 0-2 post-NPY injection interval, NPY significantly induced feeding (P = 0.0066, Fig. 7) , which was decreased 50.1% by 0.5 µg BDNF, but this did not reach statistical significance (P = 0.0645, Fig. 7 ). In the 0-4 h interval, NPY significantly increased feeding (P = 0.0131, Fig. 7) , which was significantly inhibited by 0.5 µg BDNF (54.9%, P = 0.0091, Fig. 7) .
Discussion
In the current studies, a single injection of BDNF in the VMH significantly inhibited normal feeding, deprivation-and NPY-induced feeding, and body weight gain. The conditioned taste aversion experiment suggests that BDNF at doses effective in reducing feeding did not cause taste aversion, suggesting that BDNF effects on feeding are not the result of malaise.
Unilateral injections of BDNF did not affect normal feeding in the first 4 h following injection (Fig. 3A) , but it decreased feeding and body weight gain at the 24 h and 48 h post-injection interval ( Fig. 3B and 3C ). To determine if bilateral injection of BDNF would effectively inhibit feeding, we injected BDNF bilaterally, and using a wider range of doses. Bilateral injection of BDNF dose dependently inhibited normal feeding and body weight gain (Figs. 4A and 4B) , but in general the bilateral BDNF injections were no more effective than unilateral BDNF injections in reducing feeding or body weight gain.
We also tested unilateral and bilateral administration approaches in deprivationinduced feeding. With both unilateral and bilateral injection, BDNF did not significantly affect feeding in the first 4 h post-injection interval (Results and Fig. 5A ). Both unilateral and bilateral BDNF decreased feeding at 24 h post-injection, and bilateral BDNF (same dose on each side) did not create further inhibition of feeding. At 48 h post injection, unilateral BDNF did not significantly inhibit feeding and body weight gain (Results), whereas bilateral BDNF at 0.1 -1 µg dramatically decreased feeding and body weight gain ( Fig. 5B and 5C ), suggesting that in this case the bilateral approach was more effective.
Several studies have reported inhibitory effects of BDNF on feeding after peripheral cannot cross the blood-brain barrier (60) (59). In a recent study specifically targeting the dorsal vagal complex, chronic administration of BDNF significantly decreased feeding and body weight gain at doses of 0.1 and 1.0 µg (3). As these studies relied upon a chronic infusion method, the time-course of BDNF anorectic effects is unknown. In our previous studies of BDNF in the PVN, a single BDNF injection significantly decreased feeding and body weight gain during normal, deprivation-induced, and NPY-induced feeding (86) for up to 48 h following injection. Similarly, BDNF in the VMH also shows inhibitory effects on feeding and body weight gain during this time-frame, implicating the VMH as an additional site of action for central BDNF.
The CTA experiment indicates that BDNF at effective feeding-inhibitory doses does not result in a CTA, suggesting that BDNF anorectic effects are not due to malaise or other aversive consequences of BDNF injection. Although it's possible that the temporal relationship between pairing of the novel solution exposure and potential BDNF-injection related malaise is not accurately matched, in our previous work with BDNF in the PVN, matching the saccharin exposure with the delayed timing of the anorectic response did not result in a CTA. Although not absolute, these data provide strong support for the idea that BDNF anorectic effects are not via malaise or other aversive consequences of BDNF injections.
Leptin has been reported not only to activate nuclear groups in the ventromedial hypothalamus (15, 16) (10), but also to increase BDNF mRNA and protein in the VMH (39). ICV leptin rapidly reduces food intake within 0.5-1 h post-injection (71) (53), and VMH leptin also dramatically decreases feeding and body weight (29). Since leptin stimulates BDNF expression in the VMH, it is speculated that leptin decreases feeding by mediating VMH BDNF. However, as indicated above, the timing of BDNF inhibitory effects does not match that of leptin, suggesting that BDNF may not mediate leptin feeding inhibitory effects. BDNF has also been suggested as an important downstream effector of melanocortin-4 receptor (MC4R) signaling, and one study showed that melanocortin administration stimulates BDNF expression in the VMH (89) . However, like leptin, the time-course of melanocortin-induced anorexia (19) (88) does not match that of BDNF. Although these data do not exclude BDNF interaction with either leptin or melanocortins, the timing differences in behavioral responses suggest that BDNF likely does not mediate leptin and melanocortin-induced feeding inhibition.
Several reports have indicated that the TrkB-Fc fusion protein is effective in blocking BDNF effects, such as BDNF-mediated MDA-evoked responses (37), synaptic regulation (83) , and noxious stimulation (63) . To verify that BDNF decreases feeding and body weight gain via activation of TrkB, we used the TrkB-Fc fusion protein to block BDNF binding to its receptor. Though TrkB-Fc protein does not directly target the TrkB receptor, it contains the TrkB extracellular domain (BDNF binding site), and thus acts as a competitive inhibitor of TrkB receptor binding to BDNF and reduces BDNF-TrkB signaling. Therefore this fusion protein can be used to test whether TrkB receptor binding is necessary for BDNF effects. Based on effective in-vivo concentrations (1.6-2.5 µg/µl) and in vitro ED50 data available from the manufacturer indicating that relatively large amount of the fusion protein is needed (ED50 reached when the ratio of TrkB-Fc:BDNF molecules was 6:1), we initially tested 1.5 µg TrkB-Fc, but found that this dose resulted in immediate hyperactivity, which endured for ~10-15 minutes. The dose was reduced to 0.5 µg, which did not cause hyperactivity. TrkB-Fc at 0.5 µg significantly blocked BDNF-induced feeding inhibition and body weight loss (Figs. 6A and 6B), indicating that BDNF in the VMH reduces feeding and body weight gain via its receptor TrkB.
Arc NPY neurons project to other areas of the hypothalamus including the PVN and VMH. NPY has been reported to increase feeding not only after administration into the PVN, but also after VMH injection (5, 9, 24, 31, 43, 56, 76) . We tested interactions between BDNF and NPY on feeding behavior. VMH NPY significantly increased feeding, and this effect was significantly reduced by BDNF (Fig. 7) . This finding is similar to that for PVN BDNF and NPY co-injection studies, and suggests that both VMH and PVN BDNF effects may be due to blockade of NPY orexigenic pathways.
In conclusion, BDNF in the VMH significantly decreases normal, deprivation-and NPY-induced feeding, and body weight, at doses not producing a condition taste aversion, and the effect of BDNF is mediated by its receptor TrkB in the VMH. The delayed effect on feeding inhibition suggests that BDNF in the VMH may trig activation/inhibition of neural circuit (s), or be transported to other sites for the action (1, 54) , for which further studies are needed. Together, these data implicate the VMH as an important site of BDNF action to influence energy metabolism.
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Stanley BG, Chin AS, and Leibowitz SF. A: the placement from 18 rats in the study of unilateral BDNF effect on normal feeding and deprivation-induced feeding. Two rats without correct placement were excluded from the statistic analysis. B: the placement from 17 rats in the study of bilateral BDNF effect on normal feeding. Three rats without correct placement were excluded from the statistic analysis. 
